ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of BGG on Glucose Metabolism and Other Markers of Metabolic Syndrome (Glucogold)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02834078
Recruitment Status : Completed
First Posted : July 15, 2016
Last Update Posted : July 15, 2016
Sponsor:
Collaborator:
Healthy Directions, LLC
Information provided by (Responsible Party):
Vedic Lifesciences Pvt. Ltd.

Brief Summary:

According to the International Diabetes Federation, one in every 12 individuals is a diabetic (about 8% of the world population). Major risk factors of diabetes are all the aspects of modern life which include obesity, over-weight, high-risk behavior like smoking, alcohol, multiple drug use-recreational or prescribed, environmental risk factors like inactivity and lack of exercise. However there is a window of opportunity between health and disease, which is pre-diabetes.

Pre-diabetes has been defined by American Diabetes Association as Impaired Glucose Tolerance (IGT) which is 7.8 -11.0 mmol/l, Impaired Fasting Glucose Test (IFT) which is 5.6-6.9mmol/l and now added Glycosylated Hemoglobin (HbA1c) of 5.7% to 6.4%.

Though there are plenty of drugs available for significantly impaired glucose metabolism (including oral hypoglycemic agents and insulin), their use in marginally impaired glucose metabolism is questionable due to risk of untoward hypoglycemia.

On the other hand, herbal products like curcumin, as a single ingredient has poor bioavailability problem that restricts its use as standalone treatment. Inulin works as pre-biotic and help to maintain gut microbiota which is considered as precursor for progress of prediabetes to diabetes. However, it does not have any role in primary pathophysiology of impaired glucose metabolism, i.e. pancreatic β cell dysfunction, insulin resistance, hepatic gluconeogenesis or intestinal glucose absorption. Resveratrol and omega-3 basically work on anti-oxidant pathways.

None of these popular ingredients has been studied for their role in structural and functional health of pancreatic β cells which is very important for prediction of further progress of marginally impaired glucose metabolism to significantly impaired glucose metabolism.

It is an unmet need to develop a product which not only improves insulin sensitivity, but also help to preserve the structural and functional health of pancreatic β cells. It also needs to improve overall metabolic and endothelial health of the person considering the close association between impaired glucose metabolism and these parameters.

The proposed supplement - "Berberine GlucoGold "- is an improved version of successfully marketed supplement - Berberine GlucoDefense. It has a balanced composition in which all the ingredients complement each other in such a way that along with the individual role in glucose metabolism it also takes care of overall bioavailability and stability of the supplement. As per the previous data on ingredients, the supplement is also expected to preserve the structural and functional health of pancreatic β cells. The ingredients are also known to have positive effect on overall metabolic and endothelial health. Thus BGG has been developed to address the unmet needs in the area of glucose metabolism and overall metabolic health.


Condition or disease Intervention/treatment Phase
Pre Diabetes Dietary Supplement: BGG Other: Placebo Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 126 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of 'Berberine Glucogold' [BGG] on Glucose Metabolism in Individuals With Marginally Impaired Glucose Metabolism Along With Other Markers of Metabolic Syndrome
Study Start Date : September 2015
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2016


Arm Intervention/treatment
Experimental: BGG
Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
Dietary Supplement: BGG
Placebo Comparator: Placebo
Matching placebo capsules [for BGG tablet] composed of micro crystalline cellulose and added colors and odors. Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
Other: Placebo



Primary Outcome Measures :
  1. Change in Oral Disposition Index [ Time Frame: Day 0, Day 28, Day 56 and Day 84 ]
  2. Change in Glycated hemoglobin [ Time Frame: Day 0, Day 28, Day 56 and Day 84 ]

Secondary Outcome Measures :
  1. Change in Fasting blood sugar [ Time Frame: Day 0, Day 28, Day 56 and Day 84 ]
  2. Change in Body Mass Index [ Time Frame: Day 0, Day 28, Day 56 and Day 84 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able and willing to provide informed consent.
  • Treatment naïve male-female aged 20-60 years of age.
  • BMI ≥ 25 kg/m²
  • Oral glucose tolerance test (OGTT) ≥140 and ≤250 mg/dl (pre-diabetes and early diagnosed diabetes within 45 days of diagnosis)
  • Patient with chronic stable illness can be included ONLY IF he/she is currently NOT on any of the medications included in prohibited list of medicines.
  • Currently on herbal supplements can be included after a wash-out period of 7 days.
  • Subjects willing to abstain from nicotine and alcohol in the duration of the study.

Exclusion Criteria:

  • Subjects with OGTT<140 mg/dl or ≥ 250 mg/dl
  • Current treatment with diabetes medications, including metformin
  • Current treatment with glucocorticoids
  • History of clinically significant hematological, hepatic or renal diseases, as per investigator discretion
  • Uncontrolled chronic disease
  • Hormonal Disorders
  • Subjects on Steroids
  • Subjects on Statins
  • Chronic inflammatory diseases requiring any medication
  • Migraine, Sinusitis
  • Subjects Consuming NSAIDS for long term
  • Medications include the drugs of prohibited range.
  • Pregnant and lactating females.
  • Subjects addicted to nicotine, alcohol or any other recreational drug.
  • Subjects who are planning to fast for more than 4 days/ per month during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02834078


Sponsors and Collaborators
Vedic Lifesciences Pvt. Ltd.
Healthy Directions, LLC
Investigators
Principal Investigator: Sandip Patil, M.D. Maharashtra Council of Indian Medicine
Principal Investigator: Rajesh Kewalramani, M.B.B.S. Maharashtra Council of Indian Medicine

Responsible Party: Vedic Lifesciences Pvt. Ltd.
ClinicalTrials.gov Identifier: NCT02834078     History of Changes
Other Study ID Numbers: HD/150301/BGG/PD
First Posted: July 15, 2016    Key Record Dates
Last Update Posted: July 15, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Vedic Lifesciences Pvt. Ltd.:
HbA1c
Pre Diabetes
Berberine

Additional relevant MeSH terms:
Metabolic Syndrome X
Prediabetic State
Glucose Intolerance
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Diabetes Mellitus
Endocrine System Diseases
Hyperglycemia